Alaunos Therapeutics Inc. is a clinical-stage oncology-focused cell therapy company. It focused on developing T-cell receptor therapies based on its proprietary, non-viral Sleeping Beauty gene transfer platform. Alaunos Therapeutics Inc., formerly known as Ziopharm Oncology Inc., is based in HOUSTON.
| Revenue (Most Recent Fiscal Year) | $0.01M |
| Net Income (Most Recent Fiscal Year) | $-4.68M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.94 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -66533.33% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -168.02% |
| Return on Assets (Trailing 12 Months) | -121.37% |
| Current Ratio (Most Recent Fiscal Quarter) | 3.48 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.48 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.66 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | $-2.46 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 2.21M |
| Free Float | 1.85M |
| Market Capitalization | $4.63M |
| Average Volume (Last 20 Days) | 0.34M |
| Beta (Past 60 Months) | -0.81 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 16.14% |
| Percentage Held By Institutions (Latest 13F Reports) | 27.72% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |